Proliferating cell nuclear antigen (PCNA) expression in chronic lymphocytic leukemia (CLL)

Auro Del Giglio, Susan O'brien, Richard J. Ford, John Manning, Hideyuki Saya, Michael Keating, Dennis Johnston, Dalton Fisher Chamone, Albert B. Deisseroth

研究成果: Article

25 引用 (Scopus)

抄録

Chronic Lymphocytic Leukemia (CLL) is usually an indolent disorder which in some patients assumes an aggressive clinical course. In order to assess at presentation the prognosis of a given patient, several staging systems and prognostic variables have been proposed including the expression of the Proliferating Cell Nuclear Antigen (PCNA). PCNA is a 36 kd nuclear protein, the regulation of which is cell cycle-dependent. In CLL, PCNA levels correlate with cell proliferation, clinical stage and the lymphocyte doubling time (LDT). Furthermore, preliminary data suggests that PCNA expression may also predict response to Fludarabine-based chemotherapy. Since PCNA is a cofactor for Delta DNA polymerase, PCNA overexpression in CLL may also reflect the intrinsic DNA repair activity of the leukemic cells and thus their resistance to chemotherapy. Further studies aiming at modulation of PCNA expression in CLL cells may clarify this issue and may offer a future new therapeutic strategy with which to treat this disorder.

元の言語English
ページ(範囲)265-271
ページ数7
ジャーナルLeukemia and Lymphoma
10
発行部数4-5
DOI
出版物ステータスPublished - 1993
外部発表Yes

Fingerprint

Proliferating Cell Nuclear Antigen
B-Cell Chronic Lymphocytic Leukemia
DNA Polymerase III
Drug Therapy
Nuclear Proteins
DNA Repair
Cell Cycle
Cell Proliferation
Lymphocytes

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

これを引用

Giglio, A. D., O'brien, S., Ford, R. J., Manning, J., Saya, H., Keating, M., ... Deisseroth, A. B. (1993). Proliferating cell nuclear antigen (PCNA) expression in chronic lymphocytic leukemia (CLL). Leukemia and Lymphoma, 10(4-5), 265-271. https://doi.org/10.3109/10428199309148548

Proliferating cell nuclear antigen (PCNA) expression in chronic lymphocytic leukemia (CLL). / Giglio, Auro Del; O'brien, Susan; Ford, Richard J.; Manning, John; Saya, Hideyuki; Keating, Michael; Johnston, Dennis; Chamone, Dalton Fisher; Deisseroth, Albert B.

:: Leukemia and Lymphoma, 巻 10, 番号 4-5, 1993, p. 265-271.

研究成果: Article

Giglio, AD, O'brien, S, Ford, RJ, Manning, J, Saya, H, Keating, M, Johnston, D, Chamone, DF & Deisseroth, AB 1993, 'Proliferating cell nuclear antigen (PCNA) expression in chronic lymphocytic leukemia (CLL)', Leukemia and Lymphoma, 巻. 10, 番号 4-5, pp. 265-271. https://doi.org/10.3109/10428199309148548
Giglio, Auro Del ; O'brien, Susan ; Ford, Richard J. ; Manning, John ; Saya, Hideyuki ; Keating, Michael ; Johnston, Dennis ; Chamone, Dalton Fisher ; Deisseroth, Albert B. / Proliferating cell nuclear antigen (PCNA) expression in chronic lymphocytic leukemia (CLL). :: Leukemia and Lymphoma. 1993 ; 巻 10, 番号 4-5. pp. 265-271.
@article{21860e91ff7e48fd8070c722a6a577b6,
title = "Proliferating cell nuclear antigen (PCNA) expression in chronic lymphocytic leukemia (CLL)",
abstract = "Chronic Lymphocytic Leukemia (CLL) is usually an indolent disorder which in some patients assumes an aggressive clinical course. In order to assess at presentation the prognosis of a given patient, several staging systems and prognostic variables have been proposed including the expression of the Proliferating Cell Nuclear Antigen (PCNA). PCNA is a 36 kd nuclear protein, the regulation of which is cell cycle-dependent. In CLL, PCNA levels correlate with cell proliferation, clinical stage and the lymphocyte doubling time (LDT). Furthermore, preliminary data suggests that PCNA expression may also predict response to Fludarabine-based chemotherapy. Since PCNA is a cofactor for Delta DNA polymerase, PCNA overexpression in CLL may also reflect the intrinsic DNA repair activity of the leukemic cells and thus their resistance to chemotherapy. Further studies aiming at modulation of PCNA expression in CLL cells may clarify this issue and may offer a future new therapeutic strategy with which to treat this disorder.",
keywords = "Chronic lymphocytic leukemia, CLL, PCNA, Proliferating cell nuclear antigen",
author = "Giglio, {Auro Del} and Susan O'brien and Ford, {Richard J.} and John Manning and Hideyuki Saya and Michael Keating and Dennis Johnston and Chamone, {Dalton Fisher} and Deisseroth, {Albert B.}",
year = "1993",
doi = "10.3109/10428199309148548",
language = "English",
volume = "10",
pages = "265--271",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "4-5",

}

TY - JOUR

T1 - Proliferating cell nuclear antigen (PCNA) expression in chronic lymphocytic leukemia (CLL)

AU - Giglio, Auro Del

AU - O'brien, Susan

AU - Ford, Richard J.

AU - Manning, John

AU - Saya, Hideyuki

AU - Keating, Michael

AU - Johnston, Dennis

AU - Chamone, Dalton Fisher

AU - Deisseroth, Albert B.

PY - 1993

Y1 - 1993

N2 - Chronic Lymphocytic Leukemia (CLL) is usually an indolent disorder which in some patients assumes an aggressive clinical course. In order to assess at presentation the prognosis of a given patient, several staging systems and prognostic variables have been proposed including the expression of the Proliferating Cell Nuclear Antigen (PCNA). PCNA is a 36 kd nuclear protein, the regulation of which is cell cycle-dependent. In CLL, PCNA levels correlate with cell proliferation, clinical stage and the lymphocyte doubling time (LDT). Furthermore, preliminary data suggests that PCNA expression may also predict response to Fludarabine-based chemotherapy. Since PCNA is a cofactor for Delta DNA polymerase, PCNA overexpression in CLL may also reflect the intrinsic DNA repair activity of the leukemic cells and thus their resistance to chemotherapy. Further studies aiming at modulation of PCNA expression in CLL cells may clarify this issue and may offer a future new therapeutic strategy with which to treat this disorder.

AB - Chronic Lymphocytic Leukemia (CLL) is usually an indolent disorder which in some patients assumes an aggressive clinical course. In order to assess at presentation the prognosis of a given patient, several staging systems and prognostic variables have been proposed including the expression of the Proliferating Cell Nuclear Antigen (PCNA). PCNA is a 36 kd nuclear protein, the regulation of which is cell cycle-dependent. In CLL, PCNA levels correlate with cell proliferation, clinical stage and the lymphocyte doubling time (LDT). Furthermore, preliminary data suggests that PCNA expression may also predict response to Fludarabine-based chemotherapy. Since PCNA is a cofactor for Delta DNA polymerase, PCNA overexpression in CLL may also reflect the intrinsic DNA repair activity of the leukemic cells and thus their resistance to chemotherapy. Further studies aiming at modulation of PCNA expression in CLL cells may clarify this issue and may offer a future new therapeutic strategy with which to treat this disorder.

KW - Chronic lymphocytic leukemia

KW - CLL

KW - PCNA

KW - Proliferating cell nuclear antigen

UR - http://www.scopus.com/inward/record.url?scp=0027267449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027267449&partnerID=8YFLogxK

U2 - 10.3109/10428199309148548

DO - 10.3109/10428199309148548

M3 - Article

C2 - 8106065

AN - SCOPUS:0027267449

VL - 10

SP - 265

EP - 271

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 4-5

ER -